Exhibit 5.1

April 20, 2026

PAVmed Inc.

360 Madison Avenue, 25^th Floor

New York, New York 10017

Re: Registration Statement

Ladies and Gentlemen:

We have acted as counsel for PAVmed Inc., a Delaware corporation (“Company”), in connection with the preparation of the Registration Statement on Form S-3 (“Registration Statement”) filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Act”), relating to the proposed offer and sale by the selling stockholders set forth in the Registration Statement (the “Selling Stockholders”) of 9,230,786 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”). In February 2026, the Company sold to certain accredited investors (the “Investors”), in a private placement, (i) 30,000 shares of Series D convertible preferred stock, par value $0.001 per share (the “Series D Preferred Stock”), and (ii) warrants (the “Warrants”) to purchase an additional 30,000 shares of Series D Preferred Stock, with each Investor receiving 100 shares of Series D Preferred Stock and a warrant to purchase 100 shares of Series D Preferred Stock for each $100,000 of its investment (the “Private Placement”). In March 2026, the 30,000 outstanding shares of Series D Preferred Stock sold in the Private Placement were converted in accordance with their terms into 4,615,393 shares of Common Stock. The 9,230,786 shares of Common Stock consist of the 4,615,393 shares of Common Stock (the “Conversion Shares”) issued upon conversion of the Series D Preferred Stock and the 4,615,393 shares of Common Stock (the “Warrant Shares”) issuable upon conversion of the Series D Preferred Stock underlying the Warrants.

In rendering the opinions set forth below, we have examined (a) the Registration Statement and the exhibits thereto; (b) the subscription agreements providing for the sale of the Series D Preferred Stock; (c) the form of the Warrants; (d) the Company’s Certificate of Incorporation, as amended and restated and further amended to date (“Certificate of Incorporation”); (e) the Company’s Bylaws, as amended and restated to date (“Bylaws”); (f) certain records of the Company’s corporate proceedings as reflected in its minute books; and (g) such statutes, records and other documents as we have deemed relevant.

In our examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, and the conformity with the originals of all documents submitted to us as forms or copies thereof. As to questions of fact material to this opinion, we have, to the extent deemed appropriate, relied upon certain representations of certain officers and employees of the Company.

Based upon and subject to the foregoing, we are of the opinion that:

1. The Conversion Shares have been duly authorized and are legally issued, fully paid and nonassessable.

2. The Warrant Shares to be issued by the Company upon conversion of the Series D Preferred Stock underlying the Warrants (or upon exercise of the Warrants, if the Company elects to issue the Warrant Shares upon exercise of the Warrants) have been duly authorized and, when issued upon such exercise in accordance with the terms of the Series D Preferred Stock or the Warrants, as applicable, will be legally issued, fully paid and nonassessable.

No opinion is expressed herein other than as to the corporate law of the State of Delaware.

We hereby consent to the use of this opinion as Exhibit 5.1 to the Registration Statement, to the use of our name as counsel to the Company, and to all references made to us in the Registration Statement and the prospectuses forming a part thereof. In giving this consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations promulgated thereunder.